AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has finalized pre-clinical drug studies on the patent waiting for compound SPX-1009, showing malignant metastatic melanoma cells suppression. Dr. Douglas Lake’s lab at Arizona State University completed the independent research.
AXIM finalizes SPX-1009 studies
John W. Huemoeller II, AXIM Biotechnologies CEO, said, “We are extremely excited with the results of the in vitro testing. This potential therapeutic treatment could someday help control melanoma growth and metastasis with our compound SPX-1009 in a topical treatment.”
The study screened SPX-1009 in a cell-free enzymatic assay for the ability to suppress Quiescin Sulfhydryl oxidase I (QSOXI). QSOXI is a tumor-derived enzyme vital in cancer growth, metastasis, and invasion, which was tested for the ability to suppress invasion and growth of established A375 melanoma cell line and the low-passage patient der4eived melanoma. The study employed 3D tumor spheroid assays and 2D invasion assays to ascertain the compounds’ impact on tumor suppression.
The company’s next step is initiating animal studies to show SPX-1009’s ability to suppress metastasis and tumor growth in a murine melanoma model. In addition, the IP related to the SPX-1009 tech is subject to various patent-pending applications.
AXIM files for emergency approval for ImmunoPass
AXIM Biotechnologies recently announced that Empowered Diagnostics, its manufacturing partner, had filed an emergency approval for ImmunoPass. ImmunoPass is the company’s rapid test that measures COVID-19 neutralizing antibody levels to establish the presence of neutralizing antibodies in whole blood.
Huemoeller II said, “The COVID-19 pandemic itself is evidence that the world is interconnected. Because of that, it’s crucial that countries work together to resolve this global issue and have a consistent level of care in order to achieve relative normalcy as quickly as possible. In addition, ImmunoPass is incredibly easy to use and delivers accurate results in a matter of minutes, making it an ideal device for global use.”
Curaleaf Holdings Inc (OTCMKTS: CURLF) Is Opening a Dispensary at State College
Post Views: 504 Curaleaf Holdings Inc (OTCMKTS: CURLF) is opening a State College Dispensary at 1248 A Atherton St, State...
Puration Inc (OTCMKTS: PURA) Is About to Make Its First Collaboration in the Asia Pacific
Post Views: 830 Puration Inc (OTCMKTS: PURA) is about to strike a deal for its first collaboration in the Asia...
Harborside Inc (OTCMKTS: HBORF) Will Convert Multiple Voting Shares Into Subordinate Voting Shares
Post Views: 3,121 Harborside Inc (OTCMKTS: HBORF) has announced that it will convert its outstanding and issued multiple voting shares...
Trulieve Cannabis Corp (OTCMKTS: TCNNF) Announces Partnership With Khalifa Kush
Post Views: 713 Trulieve Cannabis Corp (OTCMKTS: TCNNF) Khalifa Kush has announced an exclusive partnership. Khalifa Kush is a brand...
Indiva Ltd (OTCMKTS: NDVAF) Launches Jewel Cannabis Tarts
Post Views: 703 Indiva Ltd (OTCMKTS: NDVAF) recently launched Jewel Cannabis Tarts, its latest products into the cannabis Industry. The...
Neptune Wellness Solutions Inc’s (NASDAQ: NEPT) Subsidiary, Sprout Organics, Executes a Partnership With Cocomelon for the Distribution of Organic Produce
Post Views: 976 Sprout Organics, a subsidiary of Neptune Wellness Solutions Inc (NASDAQ; NEPT), recently announced the execution of its...